Ranibizumab News and Research RSS Feed - Ranibizumab News and Research

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today. [More]
Professor receives award for development of anti-angiogenic therapy for retinal disease

Professor receives award for development of anti-angiogenic therapy for retinal disease

Napoleone Ferrara, MD, distinguished professor of pathology and distinguished adjunct professor of ophthalmology at the University of California, San Diego School of Medicine and senior deputy director for basic sciences at UC San Diego Moores Cancer Center, was named today as one of seven recipients of the Ant-nio Champalimaud Vision Award in Lisbon, Portugal. [More]
Pfenex reports total revenue of $3.3 million for second quarter 2014

Pfenex reports total revenue of $3.3 million for second quarter 2014

Pfenex Inc., a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today provided a business update and reported financial results for the second quarter ended June 30, 2014. [More]
iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics, today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). [More]
Choroidal consequences differ between anti-VEGF therapies

Choroidal consequences differ between anti-VEGF therapies

Aflibercept’s possession of a fragment crystallisable region may make it more likely to induce unwanted effects in retinal and choroidal vessels than other anti-vascular endothelial growth factor therapies, say researchers. [More]
Study shows high BP drugs may raise likelihood of age-related macular degeneration

Study shows high BP drugs may raise likelihood of age-related macular degeneration

There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to a study published online in Ophthalmology, the journal of the American Academy of Ophthalmology. [More]
Viewpoints: Political stand-off on insurance industry safeguards; VA's problems may lie in how government works

Viewpoints: Political stand-off on insurance industry safeguards; VA's problems may lie in how government works

The Obama administration calls it an adjustment, Republicans call it a bailout and insurance companies call it the one thing that might keep them from raising rates and angering policyholders. [More]
Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Researchers have failed to find a significant genotypic effect on ranibizumab treatment response in Korean patients with neovascular age-related macular degeneration. [More]

Ranibizumab trial gets promising results for CNV

Patients with visual impairment due to myopic choroidal neovascularisation achieve better visual acuity after 3 months of individualised treatment with ranibizumab than with verteporfin photodynamic therapy, show the results of a phase III randomised controlled trial. [More]
Competitive Intelligence Report on biosimilar and biosuperior therapeutic antibodies

Competitive Intelligence Report on biosimilar and biosuperior therapeutic antibodies

Research and Markets has announced the addition of the "Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies" report to their offering. [More]
Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak. [More]

No added benefit from aflibercept, shows study

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether aflibercept (trade name: Eylea) offers an added benefit over the appropriate comparator therapy in visual impairment due to macular oedema following occlusion of the central retinal vein. [More]
Promising technique for treating eye disease proves effective in preclinical studies

Promising technique for treating eye disease proves effective in preclinical studies

A promising technique for treating human eye disease has proven effective in preclinical studies and may lead to new treatments to prevent blindness, according to experiments conducted at The Scripps Research Institute in La Jolla, California. [More]
Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date. [More]

Eylea can ease vision problems for wet AMD patients

There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected into the eyes, Avastin and Lucentis, eased symptoms for sufferers, especially those in the advanced, "wet" stage of the disease, when blood vessels in the eye become swollen and leak fluids in the eye. [More]

Aflibercept drug used for AMD shows no added benefit over current standard therapy

The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy. [More]
New study suggests that Ranibizumab can be potential prophylaxis for PVR

New study suggests that Ranibizumab can be potential prophylaxis for PVR

Proliferative vitreoretinopathy, or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, lacks effective treatment options, and substantially reduces an individual's quality of life. [More]
AACR recognizes scientists whose contributions to cancer field have extraordinary impact

AACR recognizes scientists whose contributions to cancer field have extraordinary impact

Five University of California, San Diego scientists and professors are among the first class of the Fellows of the American Association for Cancer Research Academy, created to recognize researchers whose scientific contributions have propelled significant innovation and progress against cancer. [More]
Antibiotic prophylaxis after IVT may be harmful

Antibiotic prophylaxis after IVT may be harmful

Researchers are warning against routine antibiotic prophylaxis with intravitreal injection after finding that the practice can increase the antibiotic resistance of ocular surface flora. [More]
UCSD molecular biologist to receive Breakthrough Prize in Life Sciences

UCSD molecular biologist to receive Breakthrough Prize in Life Sciences

Napoleone Ferrara, MD, PhD, the molecular biologist credited with helping decipher how tumors grow and now senior deputy director for basic sciences at the University of California, San Diego Moores Cancer Center, was today named one of 11 recipients of the inaugural Breakthrough Prize in Life Sciences, which comes with a $3 million cash award. [More]